BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11532998)

  • 1. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir.
    Taylor S; Back DJ; Drake SM; Workman J; Reynolds H; Gibbons SE; White DJ; Pillay D
    J Antimicrob Chemother; 2001 Sep; 48(3):351-4. PubMed ID: 11532998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
    Isaac A; Taylor S; Cane P; Smit E; Gibbons SE; White DJ; Drake SM; Khoo S; Back DJ
    J Antimicrob Chemother; 2004 Aug; 54(2):498-502. PubMed ID: 15254024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
    Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
    Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
    Koks CH; Crommentuyn KM; Hoetelmans RM; Burger DM; Koopmans PP; Mathôt RA; Mulder JW; Meenhorst PL; Beijnen JH
    Br J Clin Pharmacol; 2001 Jun; 51(6):631-5. PubMed ID: 11422025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
    Klaus BD; Grodesky MJ
    Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1149-67. PubMed ID: 22155899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
    Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor penetration of the male genital tract by HIV-1 protease inhibitors.
    Taylor S; Back DJ; Workman J; Drake SM; White DJ; Choudhury B; Cane PA; Beards GM; Halifax K; Pillay D
    AIDS; 1999 May; 13(7):859-60. PubMed ID: 10357387
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
    van Praag RM; Weverling GJ; Portegies P; Jurriaans S; Zhou XJ; Turner-Foisy ML; Sommadossi JP; Burger DM; Lange JM; Hoetelmans RM; Prins JM
    AIDS; 2000 Jun; 14(9):1187-94. PubMed ID: 10894283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
    Hugen PW; Verweij-van Wissen CP; Burger DM; Wuis EW; Koopmans PP; Hekster YA
    J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):139-49. PubMed ID: 10360433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
    Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
    Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.
    Valer L; De Mendoza C; De Requena DG; Labarga P; García-Henarejos A; Barreiro P; Guerrero F; Vergara A; Soriano V;
    AIDS; 2002 Sep; 16(14):1964-6. PubMed ID: 12351959
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
    Justesen US; Andersen AB; Klitgaard NA; Brøsen K; Gerstoft J; Pedersen C
    Clin Infect Dis; 2004 Feb; 38(3):426-9. PubMed ID: 14727216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.